Lb Pharmaceuticals (LBRX) Other Non-Current Liabilities (2024 - 2026)

Lb Pharmaceuticals' Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.3 million, down 46.37% from the prior year.
• Other Non-Current Liabilities fell to $1.1 million in Q1 2026 per LBRX's latest filing, from $1.3 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $2.5 million in Q4 2024 and bottomed at $942000.0 in Q3 2025.
• The 3-year median for Other Non-Current Liabilities is $1.2 million (2025), against an average of $1.5 million.
• Biggest YoY gain for Other Non-Current Liabilities was 46.37% in 2025; the steepest drop was 46.37% in 2025.
• Year by year, Other Non-Current Liabilities stood at $2.5 million in 2024, then slumped by 46.37% to $1.3 million in 2025, then declined by 14.89% to $1.1 million in 2026.
• Per Business Quant, the three latest LBRX Other Non-Current Liabilities figures stand at $1.1 million (Q1 2026), $1.3 million (Q4 2025), and $942000.0 (Q3 2025).